BioCardia has received CE Mark approval for its Morph AccessPro steerable introducer, designed for easier navigation through the vasculature during delivery of biotherapeutics and medical devices.

Incorporating the thin-walled catheter shaft technology, Morph AccessPro provides a flexible pathway that medical instruments such as balloon dilation catheters, stents, guidewires and micro infusion systems may be introduced into the peripheral vasculature.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

BioCardia has designed the steerable introducer to enhance physician control, and reduce complications and catheter exchanges. The device minimises procedure time and radiation exposure.

"It also has future potential to enhance biotherapeutic interventions for diseases of the organs fed by these arteries, such as inflammatory bowel diseases, renal diseases, and even diseases involving the pancreas."

According to BioCardia, the currently available guide catheters have pre-formed distal curves shaped similar to a hockey stick or a shepherd’s crook designed to manoeuvre within specific vascular anatomical configurations.

In general, the access could be difficult and prolonged to attain if a patient’s anatomy is complicated and does not match the catheter shape.

Through the Morph AccessPro steerable introducer, physicians can customise the catheter shape to an individual patient’s anatomy. This allows access to the contra-lateral superficial femoral artery all the way down to the trifurcation, the renal arteries and the mesenteric arteries.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

University of Utah associate professor of medicine and interventional cardiology chief Dr Rodney S Badger said: "This introducer is valuable today to improve access for aorto-ostial procedures, thereby enhancing safety and shortening procedure times.

"It also has future potential to enhance biotherapeutic interventions for diseases of the organs fed by these arteries, such as inflammatory bowel diseases, renal diseases, and even diseases involving the pancreas."

The company is currently planning to launch the Morph AccessPro steerable introducers in the EU in the coming months.

The Morph AccessPro is currently being used commercially in 350 US hospitals and has been used in thousands of cases to date.

BioCardia’s current products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact